PMID- 22614632
OWN - NLM
STAT- MEDLINE
DCOM- 20121019
LR  - 20181201
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Linking)
VI  - 30
IP  - 2
DP  - 2012 Aug
TI  - Protective effects of atorvastatin against oxidized LDL-induced downregulation of 
      KLF expression in EA.hy926 cells.
PG  - 330-6
LID - 10.3892/ijmm.2012.999 [doi]
AB  - Kruppel-like transcription factors (KLFs) play a key role in both vascular 
      development and pathophysiological processes, but little is known about the 
      relationship between KLFs and oxidized low-density lipoprotein (ox-LDL). We 
      investigated the effects of ox-LDL on KLF expression. Furthermore, since 
      atorvastatin is commonly used to treat high cholesterol, we also examined the 
      role of this drug in the regulation of KLF expression. The human umbilical vein 
      endothelial cell line EA.hy926 was treated with atorvastatin and ox-LDL alone or 
      in combination, and KLF expression was examined by DNA microarray, 
      semi-quantitative real-time PCR, western blot and immuno fl uorescence analyses. 
      Atorvastatin upregulated KLF expression in EA.hy926 cells in both the quiescent 
      and ox-LDL-induced inflammatory states, suggesting that KLFs were novel 
      participants in the vascular endothelial dysfunction response to ox-LDL. Our 
      study demonstrated that atorvastatin increased both the mRNA and protein levels 
      of KLF in quiescent EA.hy926 cells. Moreover, atorvastatin counteracted the 
      ox-LDL-induced downregulation of KLF expression.
FAU - Gao, Yan
AU  - Gao Y
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing 
      100853, P.R. China.
FAU - Liu, Xian-Feng
AU  - Liu XF
FAU - Lu, Xue-Chun
AU  - Lu XC
FAU - Ma, Cong
AU  - Ma C
FAU - Cao, Jian
AU  - Cao J
FAU - Fan, Li
AU  - Fan L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120514
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (Heptanoic Acids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Pyrroles)
RN  - 0 (oxidized low density lipoprotein)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Atorvastatin
MH  - Cytoprotection
MH  - Down-Regulation/*drug effects/genetics
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation/drug effects
MH  - Heptanoic Acids/*pharmacology
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology
MH  - Kruppel-Like Transcription Factors/genetics/*metabolism
MH  - Lipoproteins, LDL/*pharmacology
MH  - Pyrroles/*pharmacology
MH  - Reproducibility of Results
MH  - Resting Phase, Cell Cycle
EDAT- 2012/05/23 06:00
MHDA- 2012/10/20 06:00
CRDT- 2012/05/23 06:00
PHST- 2012/02/19 00:00 [received]
PHST- 2012/04/12 00:00 [accepted]
PHST- 2012/05/23 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/10/20 06:00 [medline]
AID - 10.3892/ijmm.2012.999 [doi]
PST - ppublish
SO  - Int J Mol Med. 2012 Aug;30(2):330-6. doi: 10.3892/ijmm.2012.999. Epub 2012 May 
      14.